Patents Assigned to IDAC Theranostics, Inc.
-
Patent number: 11168137Abstract: Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.Type: GrantFiled: June 10, 2015Date of Patent: November 9, 2021Assignees: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYOInventors: Satoru Ito, Shoji Yokochi, Kouji Matsushima, Satoshi Ueha, Yoshiro Ishiwata
-
Patent number: 10746726Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.Type: GrantFiled: December 2, 2015Date of Patent: August 18, 2020Assignees: THE UNIVERSITY OF TOKYO, IDAC THERANOSTICS, INC.Inventors: Kouji Matsushima, Satoshi Ueha, Satoru Ito, Shoji Yokochi, Yoshiro Ishiwata
-
Patent number: 10738352Abstract: The present invention relates to a method of analyzing a composition of nucleic acids derived from a single cell using a microplate including a plurality of reaction wells, the microplate having one bead arranged in one reaction well, the one bead having bound thereto a plurality of molecules of single-stranded oligonucleotides, the single-stranded oligonucleotides each having a nucleic acid capture sequence exposed at the 3? end and a barcode sequence on the 5? side of the nucleic acid capture sequence, the barcode sequence including a base sequence that differs from bead to bead.Type: GrantFiled: April 7, 2015Date of Patent: August 11, 2020Assignee: IDAC THERANOSTICS, INC.Inventors: Shin-ichi Hashimoto, Shuichi Kaneko, Kouji Matsushima
-
Patent number: 10709727Abstract: The present invention relates to an antiviral drug comprising as an active ingredient a substance capable of suppressing an expression of a target gene or an activity of a protein encoded by said target gene, wherein said target gene is one or more genes having an action of retaining virus-derived nucleic acid in a host cell and selected from the group consisting of DOCK11 gene, LIPG gene, DENND2A gene, and HECW2 gene. The present invention also relates to a screening method for the antiviral drug.Type: GrantFiled: November 7, 2016Date of Patent: July 14, 2020Assignee: IDAC THERANOSTICS, INC.Inventors: Shin-ichi Hashimoto, Shuichi Kaneko, Masao Honda, Takayoshi Shirasaki, Taro Yamashita
-
Publication number: 20190315775Abstract: A phenylphthalimide derivative represented by the following general formula is provided as a phenylphthalimide derivative useful against various cancers including multiple myeloma, wherein R1 is a group containing PEG or a hydroxy C1-5 alkoxy group binding to position 4 or position 5, R2 is an amino group at position 6, and R3 and R4 are each independently a hydrogen atom, an alkyl group, an aryl group, an aralkyl group, or an aryloxy group.Type: ApplicationFiled: October 19, 2017Publication date: October 17, 2019Applicants: KEIO UNIVERSITY, IDAC THERANOSTICS, INC.Inventors: Yutaka HATTORI, Maiko MATSUSHITA, Daiju ICHIKAWA, Shuji AIDA, Takeshi SUGAI, Taketo YAMADA, Hiroshi YANAGAWA, Yoko OGAWA, Noriko TABATA, Yuko YONEMURA
-
Publication number: 20190125867Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.Type: ApplicationFiled: December 27, 2018Publication date: May 2, 2019Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYOInventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
-
Publication number: 20190022126Abstract: The present invention relates to an antiviral drug comprising as an active ingredient a substance capable of suppressing an expression of a target gene or an activity of a protein encoded by said target gene, wherein said target gene is one or more genes having an action of retaining virus-derived nucleic acid in a host cell and selected from the group consisting of DOCK11 gene, LIPG gene, DENND2A gene, and HECW2 gene. The present invention also relates to a screening method for the antiviral drug.Type: ApplicationFiled: November 7, 2016Publication date: January 24, 2019Applicant: IDAC THERANOSTICS, INC.Inventors: Shin-ichi HASHIMOTO, Shuichi KANEKO, Masao HONDA, Takayoshi SHIRASAKI, Taro YAMASHITA
-
Publication number: 20170328887Abstract: Means that enables monitoring of an anticancer effect of an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint is disclosed. The method for testing a therapeutic effect of a cancer therapy of the present invention is a method for testing a therapeutic effect of an anticancer drug comprising as an effective ingredient an anti-CD4 antibody or an anticancer drug targeting an immune checkpoint, which method comprises investigation of expression of (1) at least one immune checkpoint receptor, (2) CD8, and (3) at least one cell surface molecule selected from the group consisting of CD44 and CD45RO, on T cells using a sample derived from a patient who received the anticancer drug. Induction of a T cell population which is positive for the immune checkpoint molecule (1) and positive for CD8, and which shows high expression of CD44 and/or high expression of CD45RO, indicates that said anticancer drug is producing a therapeutic effect in said patient.Type: ApplicationFiled: December 2, 2015Publication date: November 16, 2017Applicants: The University of Tokyo, IDAC Theranostics, Inc.Inventors: Kouji MATSUSHIMA, Satoshi UEHA, Satoru ITO, Shoji YOKOCHI, Yoshiro ISHIWATA
-
Publication number: 20170166959Abstract: The present invention relates to a method of analyzing a composition of nucleic acids derived from a single cell using a microplate including a plurality of reaction wells, the microplate having one bead arranged in one reaction well, the one bead having bound thereto a plurality of molecules of single-stranded oligonucleotides, the single-stranded oligonucleotides each having a nucleic acid capture sequence exposed at the 3? end and a barcode sequence on the 5? side of the nucleic acid capture sequence, the barcode sequence including a base sequence that differs from bead to bead.Type: ApplicationFiled: April 7, 2015Publication date: June 15, 2017Applicant: IDAC THERANOSTICS, INC.Inventors: Shin-ichi Hashimoto, Shuichi Kaneko, Kouji Matsushima
-
Publication number: 20170165364Abstract: Disclosed is a novel means effective for treatment, metastasis-inhibition, and recurrence-inhibition of human solid cancer. A therapeutic agent for solid cancer according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. Said anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The therapeutic agent of the present invention produces still higher effects by combined use with antagonist or agonist against immune checkpoint molecule, small molecule anticancer agents, or the like. The therapeutic agent is also effective in suppressing recurrence and metastasis of solid cancer.Type: ApplicationFiled: February 9, 2015Publication date: June 15, 2017Applicants: IDAC THERANOSTICS, INC., THE UNIVERSITY OF TOKYOInventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
-
Publication number: 20170145099Abstract: Disclosed is a means for reducing side effects of an immune checkpoint regulator that is used as an anticancer drug or the like. A side-effect reducing agent according to the present invention comprises as an effective ingredient an anti-CD4 antibody having a high cytotoxic activity, or an anti-CD4 antibody or antigen-binding fragment thereof which antibody or fragment comprises a cytotoxic component bound thereto. The anti-CD4 antibody is a human-type chimeric antibody, humanized antibody or human antibody against human CD4. The immune checkpoint regulator may be, for example, an anti-PD-L1 antibody, an antagonistic anti-CTLA-4 antibody, or an agonistic anti-OX40 antibody.Type: ApplicationFiled: June 10, 2015Publication date: May 25, 2017Applicants: IDAC Theranostics, Inc., The University of TokyoInventors: Satoru ITO, Shoji YOKOCHI, Kouji MATSUSHIMA, Satoshi UEHA, Yoshiro ISHIWATA
-
Publication number: 20160108122Abstract: Disclosed is a novel means that enables complete cure of not only acute and chronic virus infections, but also latent retrovirus infections in which incorporation of the virus into the host chromosome has occurred. In the present invention, by destroying cells containing molecules that act as scaffolds for the virus infection in the patient's body, cells per se that have been already infected with virus are destroyed while inhibiting expansion of the virus infection in the patient's body, so that final complete cure of virus infection can be realized. The treatment of immunodeficiency virus infection may be carried out by administering an antibody or the like having high cytotoxic activity to the patient to destroy at least any of CD4 molecule-containing cells, CCR5 molecule-containing cells, and CXCR4 molecule-containing cells, preferably CD4 molecule-containing cells.Type: ApplicationFiled: May 23, 2014Publication date: April 21, 2016Applicant: IDAC Theranostics, Inc.Inventors: Satoru ITO, Shoji YOKOCHI